The prognostic molecular markers in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 3, 2002, Pages 385-392

  Qin, Lun Xiu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CATENIN; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D; CYCLIN E; CYCLINE; DNA; FAS ANTIGEN; FAS LIGAND; GELATINASE A; GELATINASE B; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLEIOTROPHIN; PROTEIN MDM2; PROTEIN P27; PROTEIN P53; PROTEIN P73; PROTEINASE; TELOMERASE; THROMBOSPONDIN; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BODY FLUID; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CELL ADHESION; CELL CYCLE; CELL DENSITY; CELL NUCLEUS; CELL PROLIFERATION; CHROMOSOME ABERRATION; DISEASE MARKER; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MEDICAL GENETICS; METASTASIS; MICROVASCULATURE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MORPHOLOGY; ONCOGENE C MYC; ONCOGENE RAS; OUTCOMES RESEARCH; PATHOLOGY; PHENOTYPE; PLOIDY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY MECHANISM; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR PROMOTION;

EID: 0036280651     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i3.385     Document Type: Review

References (119)

1. Hepatocellular carcinoma-Cause, treatment and metastasis
2. The prognostic significance of clinical and pathological features in hepatocellular carcinoma
3. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score
4. Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma
5. Moving toward an understanding of the metastatic process in hepatocellular carcinoma
6. Assessment of the biological malignancy of hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis
7. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: Relevance to tumour characteristics and prognosis
8. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?
9. Immunohistochemical study on p53, H-rasp21, c-erbB-2 protein and PCNA expression in HCC tissues of Han and minority ethnic patients
10. The Ki-67 proetin: From the known and the unknown
11. Ki-67: A proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma
12. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma
13. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma
14. High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: Correlation with tumor progression
15. Computerized nuclear morphometry of hepatocellular carcinoma and its relation to proliferative activity
16. Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations
17. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer
18. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers
19. A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome
20. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorecta carcinoma
21. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia
22. Prognostic significance of P53 histochemistry and DNA histogram parameters in head and neck malignancies
23. p53 gene mutations are associated with shorted survival in patients with advanced non-small cell lung cancer: An analysis of medically managed patients
24. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis
25. The prognostic significance of p53 tumor suppresor gene alterations in ovarian carcinoma
26. Prognostic impact of P53 status in Ewing sarcoma
27. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer
28. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci
29. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: Prognostic significance
30. Circulating p53 antibody in patients with colorectal cancer: Relation to clinicopathologic features and survival
31. p53 mutation in plasma DNA and its prognostic value in breast cancer patients
32. Prognostic factors in tongue cancer - Relsative importance of demographic, clinical and histopathological factors
33. P53 determination alongside classical prognostic factors in node-negative breast cancer: An evaluation at more than 10-year follow-up
34. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years
35. Expression of p53 and p21waf1/cip1 in gastric carcinoma: Lack of inter-relationship or correlation with prognosis
36. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
37. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen
38. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder
39. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma
40. The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma
41. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma
42. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection?
43. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: With relation to tumor size and invasiveness
44. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas
45. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time
46. P53 immunohistochemistry scoring is an independent prognostic marker of patient with hepatocellular carcinoma resection: A prospective study of 256 formalin-fixed paraffin-embedded tumor samples
47. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma
48. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma
49. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma
50. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma
51. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma
52. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas
53. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma
54. p27 (Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer
55. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma
56. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence
57. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma
58. Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma
59. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection
60. Methylation status of c-fms oncogenein HCC and its relationship with clinical pathology
61. Amplification of c-myc in hepatocellular carcinoma: Correlation with clinicopathologic features, proliferative activity and p53 overexpression
62. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma
63. Gene expression of hepatocyte growth factor and its receptor in HCC and nontumorous liver tissues
64. Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas
65. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
66. Expression and possible role of ets-1 in hepatocellular carcinoma
67. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma
68. Relationship between HBxAg and Fas/FasL in patients with hepatocellular carcinoma
69. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy
70. Telomerase activity in peripheral blood for diagnosis of hepatoma
71. Quantitation of telomerase activity in hepatocellular carcinoma: A possible aid for a prediction of recurrent diseases in the remnant liver
72. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma
73. Immunoreactice E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, and patients' survival
74. Beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance
75. Abnormal Cu-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China
76. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis
77. Invasion and metastasis of liver cancer: Expression of intercellular adhesion molecule-1
78. Clinical significance of serum intercellular adhesion molecule-1 detection in patients with hepatocellular carcinoma
79. Expressions of ICAMa21 and its mRNA in sera and tissues of patients with hepatocellular carcinoma
80. CD44 cell adhesion molecules
81. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival
82. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma
83. Recurrence or metastasis of HCC: Predictors, early detection and experimental antiangiogenic therapy
84. The association of type IV collagenase with invasion and metastasis of hepatocellular carcinoma
85. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer
86. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor
87. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma
88. Circulating angiogenesis regulators in cancer patients
89. Angiogenesis in hepatocellular carcinoma as evaluated by alpha smooth muscle actin immuno histochemistry
90. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
91. Microvessel density of hepatocellular carcinoma: Its relationship with prognosis
92. Clinical implications of circulating angiogenic factors in cancer patients
93. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study
94. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma
95. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma
96. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus
97. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival
98. Allelic loss of chromosome 2p21-16. 3 is associated with reduced survival in sporadic colorectal cancer
99. Allelic losses of loci at 3p25. 1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer
100. Chromosome 9 deletions and recurrence of superficial bladder cancer: Identification of four regions of prognostic interest
101. 8pter-p23 deletion is associated with racial differences in prostate cancer outcome
102. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: Relationship to disease stage, tumor size, and cirrhosis
103. A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA
104. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma
105. Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared
106. Identification of allelic imbalances regions related to metastasis of hepatocellular carcinoma: Comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis
107. Circulating DNA in plasma or serum
108. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients
109. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas
110. Proteomic profiling from human samples: The body fluid alternative
111. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma
112. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival
113. Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma
114. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
115. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma
116. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients
117. Cloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma
118. RECK gene expression in hepatocellular carcinoma: Correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs
119. Gene expression profiling and supervised machine learning to define metastasis-related genes in human hepatocellular carcinoma